TNF Pharmaceuticals, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Mitchell Glass
- Full Time Employees
- 2
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 855 N. Wolfe Street New York City NY United States of America 21205
- IPO Date
- Jan 23, 2014
- CIK
- 0001321834
- Website
- tnfpharma.com
- Similar Companies
- Business
- TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for autoimmune, inflammatory, and age-related diseases. Founded in 2014 and headquartered in Baltimore, Maryland, the company advances two primary therapeutic platforms: its lead candidate MYMD-1, an orally bioavailable small-molecule TNF-alpha inhibitor designed to treat sarcopenia/frailty in Phase 2 trials, rheumatoid arthritis in early-stage studies, and potentially other TNF-alpha-driven conditions including those involving neuroinflammation due to its blood-brain barrier penetration; and Supera-CBD (also referred to as isomyosamine in recent updates), a synthetic cannabidiol analog that is 8,000 times more potent as a CB2 receptor agonist than plant-based CBD, targeting chronic pain, addiction, epilepsy, anxiety, sleep disorders, and inflammation. TNF Pharmaceuticals offers these assets alongside biosimilar TNF inhibitors, specialty pharmaceutical formulations such as long-acting injectables and targeted delivery systems, contract manufacturing services for complex biologics, and drug development consulting including regulatory support for IND and BLA submissions, serving global markets with emphasis on immunology, oncology, and areas of high disease burden. Recent strategic developments include a name change from MyMD Pharmaceuticals, Inc. in July 2024; a 2024 equity investment from Prevail Partners at a premium to market, paired with engagement of Prevail InfoWorks as clinical research organization for MYMD-1 Phase 2 studies; a collaboration with Renova Health using AI to identify patients for GLP-1-related inflammation interventions; an August 2025 balance sheet strengthening with liabilities reduced while maintaining over $17 million in assets; a September 2025 $7 million private placement of convertible preferred stock led by its largest stockholder to fund newly licensed light-based computing accelerator technology from LightSolver Ltd. for exclusive use in cryptocurrency and blockchain applications, prompting plans for a further name change to align with this pivot; and ongoing proxy proposals for potential reverse stock splits and equity plan amendments. The company maintains operations primarily in the United States with international partnerships and targets patients, healthcare providers, and biopharma partners worldwide.
TNF Pharmaceuticals (NASDAQ:TNFA) Trading 0.8% Higher – What’s Next?
Altimmune (NASDAQ:ALT) versus TNF Pharmaceuticals (NASDAQ:TNFA) Head-To-Head Comparison
Q/C Technologies (Formerly TNF Pharmaceuticals) Commences Trading on Nasdaq Under New Ticker Symbol “QCLS”
TNF Pharmaceuticals Announces Name Change to Q/C Technologies and New Ticker Symbol “QCLS” to Reflect Strategic Focus on Quantum Class Photonic Computing
TNF Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
TNF Pharmaceuticals Announces Closing of $7 Million Private Placement
TNF Pharmaceuticals Strengthens Financial Position for Growth and Value Creation
TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease
TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists
TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development
TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025
TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor
TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment
TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion
TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs
TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference